Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.

Link T, Passek S, Wimberger P, Frank K, Vassileva YD, Kramer M, Kuhlmann JD.

Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32676. [Epub ahead of print]

PMID:
31509615
2.

Association of caspase 8 polymorphisms -652 6N InsDel and Asp302His with progression-free survival and tumor infiltrating lymphocytes in early breast cancer.

Kuhlmann JD, Bachmann HS, Link T, Wimberger P, Kröber E, Thomssen C, Mallé B, Bethmann D, Vetter M, Kantelhardt EJ.

Sci Rep. 2019 Aug 29;9(1):12594. doi: 10.1038/s41598-019-47601-x.

3.

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.

Göbel A, Kuhlmann JD, Link T, Wimberger P, Link-Rachner C, Thiele S, Dell'Endice S, Furesi G, Breining D, Rauner M, Hofbauer LC, Rachner TD.

J Bone Oncol. 2019 Apr 4;16:100237. doi: 10.1016/j.jbo.2019.100237. eCollection 2019 Jun.

4.

Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer.

Link T, Kuhlmann JD, Kobelt D, Herrmann P, Vassileva YD, Kramer M, Frank K, Göckenjan M, Wimberger P, Stein U.

Mol Oncol. 2019 May;13(5):1268-1279. doi: 10.1002/1878-0261.12484. Epub 2019 Apr 15.

5.

Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance.

Kuhlmann JD, Chebouti I, Kimmig R, Buderath P, Reuter M, Puppel SH, Wimberger P, Kasimir-Bauer S.

Clin Chem Lab Med. 2019 Jun 26;57(7):1053-1062. doi: 10.1515/cclm-2018-1048.

PMID:
30422797
6.

Precipitation with polyethylene glycol followed by washing and pelleting by ultracentrifugation enriches extracellular vesicles from tissue culture supernatants in small and large scales.

Ludwig AK, De Miroschedji K, Doeppner TR, Börger V, Ruesing J, Rebmann V, Durst S, Jansen S, Bremer M, Behrmann E, Singer BB, Jastrow H, Kuhlmann JD, El Magraoui F, Meyer HE, Hermann DM, Opalka B, Raunser S, Epple M, Horn PA, Giebel B.

J Extracell Vesicles. 2018 Oct 17;7(1):1528109. doi: 10.1080/20013078.2018.1528109. eCollection 2018.

7.

The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro.

Schott S, Wimberger P, Klink B, Grützmann K, Puppe J, Wauer US, Klotz DM, Schröck E, Kuhlmann JD.

Oncotarget. 2017 Aug 14;8(44):76935-76948. doi: 10.18632/oncotarget.20260. eCollection 2017 Sep 29.

8.

A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, Wimberger P, Link T, Kuhlmann JD, Stenzl A, Hennenlotter J, Todenhöfer T, Rojewski M, Bieback K, Nakchbandi IA.

Cancer Res. 2018 Jan 1;78(1):129-142. doi: 10.1158/0008-5472.CAN-16-3507. Epub 2017 Oct 24.

9.

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression.

Link T, Kuithan F, Ehninger A, Kuhlmann JD, Kramer M, Werner A, Gatzweiler A, Richter B, Ehninger G, Baretton G, Bachmann M, Wimberger P, Friedrich K.

Oncotarget. 2017 Apr 29;8(33):54592-54603. doi: 10.18632/oncotarget.17523. eCollection 2017 Aug 15.

10.

Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.

Göbel A, Kuhlmann JD, Link T, Wimberger P, Browne AJ, Rauner M, Hofbauer LC, Rachner TD.

Breast Cancer Res Treat. 2017 Aug;164(3):737-743. doi: 10.1007/s10549-017-4296-3. Epub 2017 May 19.

PMID:
28526959
11.

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.

Chebouti I, Kasimir-Bauer S, Buderath P, Wimberger P, Hauch S, Kimmig R, Kuhlmann JD.

Oncotarget. 2017 Jul 25;8(30):48820-48831. doi: 10.18632/oncotarget.16179.

12.

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.

Chebouti I, Kuhlmann JD, Buderath P, Weber S, Wimberger P, Bokeloh Y, Hauch S, Kimmig R, Kasimir-Bauer S.

Oncotarget. 2017 Apr 11;8(15):24303-24313. doi: 10.18632/oncotarget.13286.

13.

Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.

Dewi DL, Mohapatra SR, Blanco Cabañes S, Adam I, Somarribas Patterson LF, Berdel B, Kahloon M, Thürmann L, Loth S, Heilmann K, Weichenhan D, Mücke O, Heiland I, Wimberger P, Kuhlmann JD, Kellner KH, Schott S, Plass C, Platten M, Gerhäuser C, Trump S, Opitz CA.

Oncoimmunology. 2017 Jan 3;6(2):e1274477. doi: 10.1080/2162402X.2016.1274477. eCollection 2017.

14.

Prognostic relevance of caspase 8 -652 6N InsDel and Asp302His polymorphisms for breast cancer.

Kuhlmann JD, Bankfalvi A, Schmid KW, Callies R, Kimmig R, Wimberger P, Siffert W, Bachmann HS.

BMC Cancer. 2016 Aug 9;16:618. doi: 10.1186/s12885-016-2662-x.

15.

Identification and Functional Testing of ERCC2 Mutations in a Multi-national Cohort of Patients with Familial Breast- and Ovarian Cancer.

Rump A, Benet-Pages A, Schubert S, Kuhlmann JD, Janavičius R, Macháčková E, Foretová L, Kleibl Z, Lhota F, Zemankova P, Betcheva-Krajcir E, Mackenroth L, Hackmann K, Lehmann J, Nissen A, DiDonato N, Opitz R, Thiele H, Kast K, Wimberger P, Holinski-Feder E, Emmert S, Schröck E, Klink B.

PLoS Genet. 2016 Aug 9;12(8):e1006248. doi: 10.1371/journal.pgen.1006248. eCollection 2016 Aug.

16.

Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

Blassl C, Kuhlmann JD, Webers A, Wimberger P, Fehm T, Neubauer H.

Mol Oncol. 2016 Aug;10(7):1030-42. doi: 10.1016/j.molonc.2016.04.002. Epub 2016 Apr 20.

17.

Targeting Cancer Stem Cells: Promises and Challenges.

Kuhlmann JD, Hein L, Kurth I, Wimberger P, Dubrovska A.

Anticancer Agents Med Chem. 2016;16(1):38-58. Review.

PMID:
26179271
18.

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.

Bachmann HS, Meier W, du Bois A, Kimmig R, Kuhlmann JD, Siffert W, Sehouli J, Wollschlaeger K, Huober J, Hillemanns P, Burges A, Schmalfeldt B, Aminossadati B, Wimberger P.

Br J Clin Pharmacol. 2015 Nov;80(5):1139-48. doi: 10.1111/bcp.12688. Epub 2015 Jul 22.

19.

Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients.

Kuhlmann JD, Wimberger P, Wilsch K, Fluck M, Suter L, Brunner G.

Clin Chem Lab Med. 2015 Mar;53(4):605-11. doi: 10.1515/cclm-2014-1064.

PMID:
25741740
20.

ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.

Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2014 Oct;60(10):1282-9. doi: 10.1373/clinchem.2014.224808. Epub 2014 Jul 11.

21.

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance.

Wimberger P, Chebouti I, Kasimir-Bauer S, Lachmann R, Kuhlisch E, Kimmig R, Süleyman E, Kuhlmann JD.

Gynecol Oncol. 2014 Jun;133(3):467-72. doi: 10.1016/j.ygyno.2014.03.574. Epub 2014 Apr 5.

PMID:
24713547
22.

Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.

Kuhlmann JD, Baraniskin A, Hahn SA, Mosel F, Bredemeier M, Wimberger P, Kimmig R, Kasimir-Bauer S.

Clin Chem. 2014 Jan;60(1):206-13. doi: 10.1373/clinchem.2013.213066. Epub 2013 Nov 8.

23.

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.

Kuhlmann JD, Schwarzenbach H, Wimberger P, Poetsch M, Kimmig R, Kasimir-Bauer S.

BMC Cancer. 2012 Jul 31;12:325. doi: 10.1186/1471-2407-12-325.

24.

microRNA and the pathogenesis of ovarian cancer--a new horizon for molecular diagnostics and treatment?

Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S.

Clin Chem Lab Med. 2012 Jan 13;50(4):601-15. doi: 10.1515/cclm-2011-0847. Review.

PMID:
22505556
25.

MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B.

Liffers ST, Munding JB, Vogt M, Kuhlmann JD, Verdoodt B, Nambiar S, Maghnouj A, Mirmohammadsadegh A, Hahn SA, Tannapfel A.

Lab Invest. 2011 Oct;91(10):1472-9. doi: 10.1038/labinvest.2011.99. Epub 2011 Jun 27.

26.

Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.

Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S.

Genes Chromosomes Cancer. 2011 Aug;50(8):598-605. doi: 10.1002/gcc.20882. Epub 2011 May 11.

PMID:
21563231

Supplemental Content

Loading ...
Support Center